DNA methylation as a molecular biomarker in gastric cancer

Tomomitsu Tahara, Tomiyasu Arisawa

研究成果: Review article

63 引用 (Scopus)

抜粋

DNA methylation plays a significant role in gastric carcinogenesis. The CpG island methylator phenotype (CIMP) characterizes distinct subtypes of gastric cancer (GC) and the relationship between specific methylation patterns and clinicopathological features has been evaluated. Altered DNA methylation is also observed in Helicobacter pylori-infected gastric mucosa, and its potential utility for GC risk estimation has been suggested. The ability to detect small amounts of methylated DNA among tissues allows us to use DNA methylation as a molecular biomarker in GC in a variety of samples, including serum, plasma and gastric washes. The DNA methylation status of nontargeted tissue, particularly blood, has been associated with predisposition to GC. We focus on the recent development of DNA methylation-based biomarkers in GC.

元の言語English
ページ(範囲)475-486
ページ数12
ジャーナルEpigenomics
7
発行部数3
DOI
出版物ステータスPublished - 01-06-2015

All Science Journal Classification (ASJC) codes

  • Genetics
  • Cancer Research

フィンガープリント DNA methylation as a molecular biomarker in gastric cancer' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用